PLANTATION, Fla., Nov. 2 /PRNewswire-FirstCall/ -- Viragen, Inc. today announced that the Company is scheduled to make a presentation at BIO-Europe 2005, the premier European biotechnology partnering conference of the year, to be held in Dresden, Germany November 7-9.
Presentation details are as follows: * Event: 11th Annual BIO-Europe 2005 Partnering Conference Presenter: Charles A. Rice, President & CEO When: Tuesday, November 8 at 9:45 a.m. (Germany) Where: Room #2, Level 4
Mr. Rice will provide updates on the pending registration of Multiferon(R) in Sweden for first-line adjuvant treatment of high-risk malignant melanoma patients, plus outline the European strategy for this important indication. In addition, the presentation will include a review of the Avian Transgenic Biomanufacturing program and the Company’s anti-cancer antibody projects.
“We believe the Multiferon(R) clinical data we submitted to the Swedish regulatory authorities is unprecedented in terms of the overall survival benefit for high-risk skin cancer patients, and we anticipate a decision this year,” stated Mr. Rice. “We expect this important approval will be a key step to implement our strategy for registration in the broader European markets.”
BIO-Europe 2005 comprises the penultimate BIO organization meeting of the calendar year with an expected record turnout of biotech and pharmaceutical companies. The conference includes two days of pre-scheduled partnering meetings, which is also expected to draw record participation.
About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a biotechnology company engaged in the research, development, manufacture and commercialization of pharmaceutical proteins for the treatment of viral diseases and cancers. Our product portfolio includes: Multiferon(R) (multi- subtype, natural human alpha interferon) targeting a broad range of infectious and malignant diseases; and humanized monoclonal antibodies targeting specific antigens over-expressed on many types of cancers. We are also pioneering the development of Avian Transgenic Technology, with the renowned Roslin Institute, as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies.
Viragen is publicly traded on the American Stock Exchange (VRA). Viragen’s majority-owned subsidiary, Viragen International, Inc., is publicly traded on the Over-The-Counter Bulletin Board (VGNI). Viragen’s key partners include: Roslin Institute, Memorial Sloan-Kettering Cancer Center, Cancer Research Technology UK, Oxford BioMedica Plc, University of Nottingham (U.K.), America’s Blood Centers and the German Red Cross.
For more information, please visit: http://www.Viragen.com Viragen, Inc. Corporate Contact: Douglas Calder, Director of Communications Phone: (954) 233-8746; Fax: (954) 233-1414 E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as “expect,” “potential,” “suggests,” “may,” “should,” “could” or similar expressions. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company’s ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
Photo: http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-bAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comViragen, Inc.
CONTACT: Douglas Calder, Director of Communications, Viragen,+1-954-233-8746, or fax, +1-954-233-1414, or dcalder@viragen.com
Web site: http://www.viragen.com/
